Starboard joins opposition to Bristol-Myers' $74 billion Celgene deal

Activist hedge fund Starboard Value LP followed Bristol-Myers Squibb Co’s second-largest investor, Wellington Management, in opposing the drugmaker’s $74 billion purchase of biotech Celgene Corp on Thursday, sowing further doubt on would be the largest pharmaceutical acquisition of all time.

…read more

Source:: Reuters – Business News